journal
MENU ▼
Read by QxMD icon Read
search

Surgical Oncology Clinics of North America

journal
https://www.readbyqxmd.com/read/28279475/updates-in-esophagogastric-cancer
#1
EDITORIAL
David H Ilson
No abstract text is available yet for this article.
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279474/gastric-and-esophageal-cancer-2017
#2
EDITORIAL
Nicholas J Petrelli
No abstract text is available yet for this article.
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279473/issues-in-the-management-of-esophagogastric-cancer-in-geriatric-patients
#3
REVIEW
Elizabeth Won
Esophagogastric cancers predominantly affect older adults; however, older patients are less likely to be recommended for both curative and palliative treatment. Older patients have unique challenges that need to be addressed during their oncologic care. Tools such as complete geriatric assessments may help to better identify fit older adults and stratify patients for aggressive treatment strategies. This review evaluates the current knowledge and the remaining challenges in optimally managing elderly patients with esophagogastric cancers...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279472/nutritional-support-in-esophagogastric-cancers
#4
REVIEW
Elliott Birnstein, Mark Schattner
Esophageal and gastric cancers are common malignancies, both in the United States and worldwide, that carry significant morbidity and mortality. Malnutrition is a common complication in patients with esophageal and gastric cancers and it portends a poor prognosis. For patients who undergo surgical therapy for these types of cancers, preoperative and postoperative nutritional optimization have been shown to improve outcomes. The support can be accomplished in different manners, including orally, enterally, or parentally...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279471/current-progress-in-human-epidermal-growth-factor-receptor-2-targeted-therapies-in%C3%A2-esophagogastric-cancer
#5
REVIEW
Yelena Y Janjigian, Maria Ignez Braghiroli
Esophagogastric cancer is a worldwide health problem. The addition of the epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab to chemotherapy increased the overall survival of patients with metastatic HER2-positive esophagogastric cancer. This article discusses the available data to support HER2 as validated biomarker and recently completed and ongoing clinical trials of HER2-directed agents in metastatic and localized disease. Also reviewed is the mechanisms of resistance for HER2-directed therapy and ongoing research strategies including new imaging techniques and studies with patient-derived xenografts...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279470/novel-targeted-therapies-for-esophagogastric-cancer
#6
REVIEW
Steven B Maron, Daniel V T Catenacci
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) is increasing in incidence. GEC, including GC and EGJ, is treated uniformly in the metastatic setting. Overall survival in the metastatic setting remains poor. Molecular characterization of GEC has identified mutations and copy number variations, along with other oncogenes, biomarkers, and immuno-oncologic checkpoints that may serve as actionable therapeutic targets...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279469/the-current-status-of-immunotherapies-in-esophagogastric-cancer
#7
REVIEW
Geoffrey Y Ku
This review summarizes completed and ongoing studies evaluating the activity of immune checkpoint inhibitors in esophagogastric cancer.
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279468/radiation-therapy-for-locally-advanced-esophageal-cancer
#8
REVIEW
Stephen G Chun, Heath D Skinner, Bruce D Minsky
The treatment of locally advanced esophageal cancer is controversial. For patients who are candidates for surgical resection, multiple prospective clinical trials have demonstrated the advantages of neoadjuvant chemoradiation. For patients who are medically inoperable, definitive chemoradiation is an alternative approach with survival rates comparable to trimodality therapy. Although trials of dose escalation are ongoing, the standard radiation dose remains 50.4 Gy. Modern radiotherapy techniques such as image-guided radiation therapy with motion management and intensity-modulated radiation therapy are strongly encouraged with a planning objective to maximize conformity to the intended target volume while reducing dose delivered to uninvolved normal tissues...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279467/controversies-and-consensus-in-preoperative-therapy-of-esophageal-and-gastroesophageal-junction-cancers
#9
REVIEW
Geoffrey Y Ku
This review summarizes established adjuvant approaches for locally advanced esophageal cancer (including preoperative, perioperative, or postoperative approaches, which include chemotherapy alone or chemoradiation). It also discusses areas of uncertainty and therapeutic equipoise.
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279466/current-progress-in-the-adjuvant-treatment-of-gastric-cancer
#10
REVIEW
David H Ilson
Staging of locally advanced gastric cancer includes imaging with computed tomography scan and laparoscopic assessment to rule out peritoneal disease or positive peritoneal washings. Preoperative and postoperative chemotherapy improves survival compared with surgery alone. After primary D2 resection, adjuvant chemotherapy with a fluorinated pyrimidine with or without a platinum agent improves survival. Inclusion of postoperative radiation therapy appears required in combination with chemotherapy in patients with less than a D1-D2 resection...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279465/the-asian-perspective-on-the-surgical-and-adjuvant-management-of-esophagogastric-cancer
#11
REVIEW
Yukinori Kurokawa, Mitsuru Sasako
In East Asia, D2 dissection has been routine surgical procedure for curable advanced gastric cancer. More extended surgery than D2 is reserved for borderline resectable disease with extended nodal metastasis. The addition of radiation therapy to adjuvant chemotherapy failed to improve the outcome after D2 dissection. Because many patients are diagnosed in East Asia with early-stage disease, postoperative adjuvant chemotherapy is preferred, and S-1 monotherapy or capecitabine-oxaliplatin is standard care. Neoadjuvant chemotherapy may be preferred for stage III tumors; for borderline resectable tumors, preoperative chemotherapy is under study given the limitations of postoperative adjuvant chemotherapy in high-risk patients...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279464/minimally-invasive-surgery-the-emerging-role-in-gastric-cancer
#12
REVIEW
Michael R Cassidy, Sepideh Gholami, Vivian E Strong
Minimally invasive surgical techniques are an emerging option in the staging and management of gastric cancer in the United States and elsewhere. Although much of the current knowledge about these approaches and their outcomes has been generated in Eastern countries, experience in the United States is growing. This article discusses both laparoscopic and robotic approaches to gastric cancer management. Important aspects of patient selection are emphasized. Surgical and oncologic outcomes are presented and compared with traditional open gastrectomy...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279463/endoscopic-management-of-early-esophagogastric-cancer
#13
REVIEW
Qurat-Ul-Ain Rizvi, Arrhchanah Balachandran, Doreen Koay, Prateek Sharma, Rajvinder Singh
Esophagogastric cancer accounts for the second most common cause of cancer-related mortality worldwide. Significant efforts have been made to detect these malignancies at an earlier stage through the implementation of screening programs in high-risk individuals using advanced diagnostic techniques. Endoscopic management techniques, such as endoscopic mucosal resection and endoscopic submucosal dissection, have consistently demonstrated excellent outcomes in the management of these lesions. These techniques are associated with a lower risk of morbidity and mortality when compared with traditional surgical management...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279462/screening-and-preventive-strategies-in-esophagogastric-cancer
#14
REVIEW
Liam Zakko, Lori Lutzke, Kenneth K Wang
Gastric adenocarcinoma, esophageal adenocarcinoma, and esophageal squamous cell carcinoma are among the most prevalent and deadly of malignancies worldwide. Screening and prevention programs will be critical to finally improving outcomes in these diseases. For gastric adenocarcinoma, screening in high-risk populations has significantly reduced mortality. More research is needed on screening high-risk individuals in low-risk populations. For esophageal adenocarcinoma, work is needed to develop efficient and effective techniques in mass screening programs...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889042/preface
#15
EDITORIAL
Cathy Eng
No abstract text is available yet for this article.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889041/anal-cancer-2016
#16
EDITORIAL
Nicholas J Petrelli
No abstract text is available yet for this article.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889040/evolution-and-management-of-treatment-related-toxicity-in-anal-cancer
#17
REVIEW
Ethan B Ludmir, Lisa A Kachnic, Brian G Czito
Over the past several decades, clinical trials have demonstrated improved disease-related outcomes in the definitive treatment of anal cancer. Although treatment with radiation and concurrent chemotherapy results in high rates of cure, significant acute and late toxicities are seen. This review focuses on the evolution of treatment-related toxicity for anal cancer. Management of these adverse effects is reviewed, as are future directions in anal cancer treatment and their impact on toxicity.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889039/epidemiology-of-anal-canal-cancer
#18
REVIEW
Valerie M Nelson, Al B Benson
Anal cancer is a rare malignancy, although its incidence has been increasingly in recent decades. This article discusses risk factors for anal cancer and how these risk factors affect the changing demographics of this disease.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889038/treatment-of-the-primary-tumor-in-anal-canal-cancers
#19
REVIEW
Rob Glynne-Jones, Sheela Rao
Radical concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C (MMC) remains the standard of care for squamous cell carcinoma of the anus. Phase III trials over 2 decades have used combined radiation doses of 50 to 60 Gy with concurrent fluoropyrimidines, MMC, or cisplatin in various doses and schedules. Modern radiotherapy techniques allow the production of highly conformal plans, decreasing radiation doses to the organs at risk and ensuring a shorter overall treatment time without the need for treatment breaks...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889037/pathology-of-anal-cancer
#20
REVIEW
Paulo M Hoff, Renata Coudry, Camila Motta Venchiarutti Moniz
Anal canal cancer is rather an uncommon disease but its incidence is increasing. Squamous cell carcinoma (SCC) is the most frequent primary anal neoplasm and can encompass a variety of morphologies. HPV infection has a key role in precancerous lesions and cancer development by the production of E6 and E7 oncoproteins. Anal squamous precancerous lesions are now classified according to the same criteria and terminology as their cervical counterparts. The p16 expression by immunohistochemistry is a surrogate marker for human papilloma virus (HPV)...
January 2017: Surgical Oncology Clinics of North America
journal
journal
31108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"